Sartorius Stedim Biotech S.A. (EPA:DIM)
France · Delayed Price · Currency is EUR 178.10
+3.40 (1.95%)
May 29, 2026, 5:35 PM CET
Sartorius Stedim Biotech Income Statement
Financials in millions EUR. Fiscal year is January - December.
Millions EUR. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 2,984 | 2,968 | 2,780 | 2,776 | 3,493 | 2,887 | |
Revenue Growth (YoY) | 41.23% | 6.74% | 0.16% | -20.53% | 20.98% | 51.15% |
Cost of Revenue | 778.6 | - | - | 1,542 | 1,675 | 1,334 |
Gross Profit | 1,334 | 1,345 | 1,207 | 1,234 | 1,817 | 1,553 |
Selling, General & Admin | 658.2 | 661.3 | 648.5 | 616 | 611.9 | 531.7 |
Research & Development | 132.3 | 133.1 | 144.1 | 129.5 | 132.4 | 110.5 |
Other Operating Expenses | 10.2 | 25.2 | 43.6 | 39.1 | 77.9 | 45.4 |
Total Operating Expenses | 800.7 | 819.6 | 836.2 | 784.6 | 822.2 | 687.6 |
Operating Income | 533.7 | 525.7 | 370.6 | 449.5 | 995.2 | 865.4 |
Interest Income | 19.2 | 40.2 | 45.4 | 94.4 | 185.8 | 22.3 |
Interest Expense | -175.8 | -192.7 | -196.7 | -141.9 | -50.7 | -241 |
Total Non-Operating Income (Expense) | -156.6 | -152.5 | -151.3 | -47.5 | 135.1 | -218.7 |
Pretax Income | 377 | 373.2 | 219.2 | 401.9 | 1,130 | 646.7 |
Provision for Income Taxes | 108.2 | 107.3 | 40.7 | 89.2 | 250.5 | 232.4 |
Net Income | 268.1 | 265.6 | 175.1 | 310.3 | 876.1 | 414.4 |
Minority Interest in Earnings | 0.4 | 0.3 | 3.4 | 2.4 | 3.8 | -0.1 |
Net Income to Common | 268.1 | 265.6 | 175.1 | 310.3 | 876.1 | 414.4 |
Net Income Growth | 125.86% | 51.69% | -43.57% | -64.58% | 111.41% | 23.36% |
Shares Outstanding (Basic) | 97 | 97 | 97 | 92 | 92 | 92 |
Shares Outstanding (Diluted) | 97 | 97 | 97 | 92 | 92 | 92 |
Shares Change (YoY) | 73.30% | 0.54% | 5.01% | -0.00% | -0.01% | -0.00% |
EPS (Basic) | 2.75 | 2.73 | 1.81 | 3.37 | 9.51 | 4.50 |
EPS (Diluted) | 2.75 | 2.73 | 1.81 | 3.37 | 9.51 | 4.50 |
EPS Growth | 30.33% | 50.83% | -46.29% | -64.56% | 111.33% | 23.63% |
Shares Outstanding | 97.3 | 97.3 | 97.3 | 92.17 | 92.17 | 92.18 |
Free Cash Flow | 370.95 | 299 | 475.3 | 272.8 | 181.7 | 377.9 |
Free Cash Flow Growth | 24.06% | -37.09% | 74.23% | 50.14% | -51.92% | 46.65% |
Free Cash Flow Per Share | 3.80 | 3.07 | 4.91 | 2.96 | 1.97 | 4.10 |
Dividends Per Share | - | 0.690 | 0.690 | 0.690 | 1.440 | 1.260 |
Dividend Growth | - | - | - | -52.08% | 14.29% | 85.29% |
Gross Margin | 44.71% | 45.33% | 43.41% | 44.46% | 52.03% | 53.79% |
Operating Margin | 17.88% | 17.72% | 13.33% | 16.20% | 28.49% | 29.98% |
Profit Margin | 9.00% | 8.96% | 6.42% | 11.27% | 25.19% | 14.35% |
FCF Margin | 12.43% | 10.08% | 17.10% | 9.83% | 5.20% | 13.09% |
EBITDA | 855.25 | 843.8 | 672.3 | 686.3 | 1,177 | 1,007 |
EBITDA Margin | 28.66% | 28.43% | 24.18% | 24.73% | 33.70% | 34.88% |
EBIT | 533.7 | 525.7 | 370.6 | 449.5 | 995.2 | 865.4 |
EBIT Margin | 17.88% | 17.72% | 13.33% | 16.20% | 28.49% | 29.98% |
Effective Tax Rate | 28.70% | 28.75% | 18.57% | 22.19% | 22.16% | 35.94% |